An overview of statin-associated proteinuria

Drug Discovery Today
Atul Tiwari

Abstract

Statins are an established therapeutic modality for the treatment of hypercholesterolemia. Although they generally exhibit a good efficacy and tolerability profile, their reputation has been tarnished as a result of reports of myotoxicity and, more recently, observations of proteinuria. The increased incidence of proteinuria with rosuvastatin was of particular concern, and raised questions about the renoprotective actions of statins. Different hypotheses have been put forward to explain the mechanisms of statin-induced proteinuria. The multifarious effects of statins, independent of their effects on cholesterol-lowering, form the basis of such hypotheses. However, rosuvastatin-associated proteinuria is transient and reversible and even at the highest dose did not affect renal function after prolonged treatment. It would appear that clinically relevant proteinuria is not associated solely with rosuvastatin and might represent a minor class effect of statins with a fairly low incidence. However, definitive proof of this assertion will need to be provided by rigorous testing.

References

Jan 1, 1992·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·P C ChanM T Tsang
Dec 1, 1992·Molecular Biology of the Cell·M Bomsel, K Mostov
Oct 1, 1995·Hypertension·M MänttäriV Manninen
Sep 1, 1995·Current Opinion in Nephrology and Hypertension·J L Stow
Jul 11, 1996·Nature·C LamazeS L Schmid
Feb 14, 1997·The Journal of Biological Chemistry·R VitelliC Bucci
Sep 1, 1999·Proceedings of the National Academy of Sciences of the United States of America·S M HammadW S Argraves
Jan 5, 2000·Journal of the American Society of Nephrology : JASN·Sung Il KimHi Bahl Lee
Apr 15, 2000·The Journal of Biological Chemistry·S M HammadW S Argraves
May 9, 2000·Clinical Pharmacology and Therapeutics·M BuemiN Frisina
Mar 16, 2001·American Journal of Physiology. Renal Physiology·E I Christensen, H Birn
Mar 17, 2001·Nature Reviews. Molecular Cell Biology·M Zerial, H McBride
Jun 20, 2001·Trends in Cardiovascular Medicine·J L Barth, W S Argraves
Jun 27, 2001·Expert Opinion on Investigational Drugs·J F Whitfield
Aug 29, 2001·The American Journal of Cardiology·A G OlssonA Raza
Jan 25, 2002·Current Controlled Trials in Cardiovascular Medicine·Curt D Furberg, Bertram Pitt
Mar 26, 2002·Journal of the American Society of Nephrology : JASN·Xiaojing LouMarilyn Gist Farquhar
Jul 10, 2002·Hypertension·Tsung-Ming LeeChang-Her Tsai
Jul 23, 2002·JAMA : the Journal of the American Medical Association·Joshua S BennerJerry Avorn
Jul 23, 2002·JAMA : the Journal of the American Medical Association·Cynthia A JackeviciusJack V Tu
Aug 7, 2002·The Journal of Clinical Investigation·James K Liao
Oct 9, 2002·Angiology·Moses Elisaf, Dimitri P Mikhailidis
Nov 28, 2002·The Annals of Pharmacotherapy·Jitu R Modi, Michael S Cratty
Mar 21, 2003·Biochemical and Biophysical Research Communications·Robert Roskoski
Jun 14, 2003·Pharmacology & Therapeutics·Anthony S WierzbickiAlbert Ferro
Jun 20, 2003·Proceedings of the National Academy of Sciences of the United States of America·Erik I ChristensenPierre J Courtoy
Jul 16, 2003·The American Journal of Cardiology·Peter H JonesUNKNOWN STELLAR Study Group
Mar 17, 2004·Coronary Artery Disease·Donald B HunninghakeDennis W Schneck
Apr 10, 2004·Cardiology·Donald G VidtHoward G Hutchinson
Sep 2, 2004·Journal of the American Society of Nephrology : JASN·Anja VerhulstMarc E De Broe
Sep 2, 2004·Journal of the American Society of Nephrology : JASN·James E SidawayNigel J Brunskill
Oct 20, 2004·Circulation·Folkert W AsselbergsUNKNOWN Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators
Oct 27, 2004·Expert Opinion on Drug Safety·Michael H Davidson
May 27, 2005·The New England Journal of Medicine·Jenny N PoynterGad Rennert

❮ Previous
Next ❯

Citations

Jan 29, 2010·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Michael S KostapanosMoses S Elisaf
May 3, 2014·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Michael S KostapanosMoses S Elisaf
Nov 15, 2008·Expert Opinion on Therapeutic Targets·Atul Tiwari
Aug 16, 2006·Expert Opinion on Drug Safety·Atul TiwariKasim Mookhtiar
Oct 7, 2006·Current Medical Research and Opinion·Alberico L CatapanoAndrew M Tershakovec
Mar 2, 2016·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Francesca CorteseMarco Matteo Ciccone
Aug 5, 2008·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Mahboob RahmanUNKNOWN ALLHAT Collaborative Research Group
Nov 11, 2006·Atherosclerosis·D N KiortsisE N Liberopoulos
Oct 20, 2006·Journal of Clinical Pharmacology·Michael S KostapanosMoses Elisaf
Sep 16, 2011·Journal of Biomedicine & Biotechnology·Anja VerhulstPatrick D'Haese
May 8, 2008·Journal of Cardiovascular Pharmacology and Therapeutics·Michael S KostapanosMoses S Elisaf
Sep 1, 2011·International Journal of Toxicology·Hardik DodiyaSunita S Goswami
Apr 25, 2012·Journal of Computer-aided Molecular Design·Natalie B VinhDavid K Chalmers

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

The American Journal of Cardiology
Rajiv Agarwal
The American Journal of the Medical Sciences
Rajiv Agarwal, Timothy M Curley
Angiology
M Elisaf, Dimitri P Mikhailidis
© 2022 Meta ULC. All rights reserved